CC
GNMX

Casdin Capital’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Casdin Capital’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-375,000
Closed -$1.94M – 34
2016
Q4 		$1.94M Hold
375,000
– – 1.6% 21
2016
Q3 		$2.09M Buy
375,000
+290,000
+341% +$1.65M 1.69% 20
2016
Q2 		$472K Buy
+85,000
New +$446K 0.47% 27

Other funds holding GNMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Casdin Capital's GNMX Position: Q1 2017 in Review

Casdin Capital sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2017, closing a stake of 375,000 shares — an estimated $1.94M sold.

Casdin Capital first reported a position in GNMX in Q2 2016 and held it in 3 quarters. The position peaked at $2.09M in Q3 2016. 73 funds tracked by Wall St. Rank hold GNMX as of Q1 2017.

  • Casdin Capital reported no remaining Aevi Genomic Medicine Inc position as of Q1 2017 after selling out during the quarter.
  • Casdin Capital sold 375,000 Aevi Genomic Medicine Inc shares in Q1 2017, an estimated $1.94M.
  • Casdin Capital first reported a position in Aevi Genomic Medicine Inc in Q2 2016 and held it in 3 quarters.
  • Casdin Capital's Aevi Genomic Medicine Inc position peaked at $2.09M in Q3 2016.
  • 73 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2017.

Based on Casdin Capital's 13F filing for Q1 2017, filed 15 May 2017.